GRDN

Analyst Note: GRDN (Guardian Pharmacy Services, Inc.)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Setup State: Actionable (Forming Coil)
• Aggressive/Pre-Breakout Entry: Not applicable for a confirmed signal; currently observing the formation.
• Breakout Level: The resistance level defining the top of the coil (not explicitly priced in the provided data, but implied to be near or above the current $42.41).
• Current Price: $42.41.
• Extension: None (Price is within the coil structure, not extended above resistance).
• ATR Context: Current ATR is 3.7% (Productive). This sits within the historical "sweet spot" (4–6% is ideal, 3.7% is slightly below but indicates manageable volatility for positioning).

2. Thesis Layer

• Thesis Status: TACTICAL / SETUP-LED.
• Analysis: As of 2026-06-13, there is no named secular thesis attached to this specific setup in the current data layer. The investment case is not driven by a macro narrative (e.g., "Silver Tsunami" is a background industry trend, not a specific catalyst for this trade). The conviction must be derived entirely from the quality of the price structure (the forming coil) and the underlying business fundamentals reported in the most recent earnings and filings. Do not invent a thesis; judge the setup on its structural integrity and the company's operational execution.

3. Business Overview

Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider specializing in long-term care facilities (LTCFs). The company delivers tech-driven solutions, including personalized clinical assistance, efficient drug distribution, and administrative support.

• Business Model: The company enters into contracts directly with LTCFs to serve as the principal pharmacy provider for their residents. Revenue is derived primarily from residents in Assisted Living Facilities (ALFs) and Behavioral Health Facilities (BHFs), which account for more than two-thirds of annual revenue. The remainder comes from Skilled Nursing Facilities (SNFs).
• Scale & Reach (as of Q1 2026):
• Residents Served: Approximately 207,000 residents (up from 205,000 at year-end 2025).
• Facilities: Served approximately 8,400 LTCFs across 38 states.
• Infrastructure: Operates 61 pharmacies, 54 of which are full-service.
• Market Position: Claims to be the largest LTCF pharmacy in the U.S. by market share serving ALF/Memory Care facilities, with an approximate 13.0% national market share (based on NIC MAP Vision data as of Dec 31, 2025).
• Revenue Drivers:
• Payer Mix: Approximately 71% of revenue is derived from Medicare Part D.
• Growth Metrics: Script volumes increased 10% year-over-year. Total residents increased 10% year-over-year.
• Guidance: Management provided updated adjusted EBITDA guidance of $123 million to $127 million (up from $120 million to $124 million).
• Strategic Initiatives:
• Acquisitions: Management expects to continue a historical pace of acquisitions in 2026, with active discussions on strategic candidates.
• Infrastructure: Targeted hiring to build out regional organizational infrastructure, which management expects will cause labor costs to trend modestly higher.
• Technology: Utilizes "Guardian Compass" for data dashboards and "GuardianShield Programs" for dedicated LTCF support.
• Legal/Regulatory: A payor-reimbursement matter was settled via a final mutual release on April 21, 2026.

4. Archetype and Conviction Stack

• Archetype: Margin Inflector.
• Rationale: The company is demonstrating the ability to grow revenue (10% resident growth, 10% script volume growth) while simultaneously expanding EBITDA guidance. The "Margin Inflector" label fits because the company is scaling its infrastructure (hiring, acquisitions) to capture more of the market, with management explicitly noting that absent government-mandated price declines, revenue growth would have been "low double digits." The focus on ALFs/BHFs (lower acuity but high volume) and the settlement of reimbursement issues suggest a path to margin expansion through scale and operational efficiency.
• Valuation Context:
• Forward consensus EPS (FY1) is $1.26; FY2 is $1.36.
• At a current price of $42.41, the stock trades at approximately 33.6x FY1 EPS. This is a premium valuation for a pharmacy services company, implying the market is pricing in significant execution of the growth and margin inflection thesis.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. Recent earnings (May 2026) and filings (March 2026) provide concrete data on resident growth, script volume, and EBITDA guidance.
• Structural Quality: Moderate/Positive. The "Forming Coil" indicates a healthy consolidation phase. The ATR of 3.7% suggests the stock is not in a chaotic state but is building a base.
• Setup Readiness: Partial. The setup is "Forming," meaning it is not yet actionable for a conservative breakout entry. It requires a confirmed breakout above the coil resistance to be considered "Confirmed-Active."
• Rerating Potential: Moderate. If the company continues to execute on its acquisition strategy and maintains the 10% growth trajectory while managing labor costs, the premium valuation could be justified. However, the lack of a named secular thesis limits the rerating ceiling to purely fundamental execution.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• Fundamental: A significant miss on the updated EBITDA guidance ($123M–$127M) or a reversal in the 10% resident/script growth trend.
• Regulatory: New government-mandated price declines that exceed the "low double digits" organic growth, compressing margins.
• What Would Strengthen:
• Price Action: A confirmed breakout above the coil resistance with volume, moving the setup to "Confirmed-Active."
• Fundamental: Successful closing of acquisition candidates that accrete earnings, or a further upward revision of EBITDA guidance.
• Operational: Confirmation that labor cost increases are manageable and do not erode the EBITDA margin expansion.
• Gaps in Evidence:
• Acquisition Details: While acquisitions are mentioned, specific deal terms, pricing, or immediate accretion impact are not detailed.
• Labor Cost Quantification: Management expects labor costs to trend "modestly higher," but no specific percentage or dollar impact is quantified.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) 10% year-over-year growth in both residents and script volumes; 2) Updated EBITDA guidance raised to $123M-$127M; 3) Market leader position with 13% share in ALF/MC segment; 4) Forming coil structure holding above support with productive ATR. Key risks: 1) Premium valuation (33x FY1 EPS) requires flawless execution; 2) Government-mandated price declines could outpace organic growth; 3) Rising labor costs from infrastructure build-out may compress margins; 4) Setup is "Forming" and not yet a confirmed breakout. Sizing hint: Position size should be conservative given the "Forming" status and lack of a confirmed breakout; treat as a partial position awaiting confirmation. Expected path: Management expects continued organic growth and acquisition activity; if price breaks out of the coil, the setup transitions to "Confirmed-Active" with potential for multiple expansion. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).